Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life

• Autor(a) principal: Girolineto, Beatriz Maria Pereira
• Data de Publicação: 2012
• Outros Autores: Junior, Veriano Alexandre, Sakamoto, Américo Ceiki, Pereira, Leonardo Régis Leira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/46159
• topic: Epilepsy^i1^streatm; Lamotrigine^i1^stherapeutic equivale; Drugs^i1^sinterchangeabil

Epilepsy is the most common serious neurological disorder worldwide. Approximately 70% of patients with epilepsy have their seizures controlled by clinical and pharmacological treatment. This research evaluated the possible influence of interchangeability among therapeutic equivalents of LTG on the clinical condition and quality of life of refractory epileptic patients. The study was divided into three periods of 42 days, and an equivalent therapeutic LTG randomly dispensed for each period (two similars - formulations A and B, and the reference product - formulation C). The mean dose of LTG was 5.5 mg/kg/day. The presence of side effects tends to have a greater deleterious effect on quality of life of refractory epileptics compared to variations in number of seizures or changes in plasma concentrations. The results showed that independently of the drug prescribed, interchangeability among therapeutic equivalents can negatively impact epilepsy control.